Viatris stock price recently touched $11

Viatris stock price recently touched $11.35, reflecting investor optimism on global generic drug demand. The RSI indicates the stock is neither overbought nor oversold, opening the door for possible breakout in Q Amphastar Pharmaceuticals reported revenues of $191.2 million, up 5.9% year on year, falling short of analysts’ expectations by 1%. It was a softer quarter as it posted a miss of analysts’ EPS estimates. Sales from Emerging Markets were under pressure in the first quarter due to the impact of the Indore facility and customer buying patterns on the generics business. Nonetheless, growth in brands across the cardiovascular portfolio in certain Latin American countries and continued strengths in the Middle East and North America and Eurasia regions have likely offset this impact in the second quarter. Closing slightly up at $11.32, the Viatris stock price benefited from defensive sector inflows as investors sought healthcare stability amid macroeconomic uncertainty.